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Abstract: Deeper understanding of the pathobiology of non-small-cell lung cancer (NSCLC) 
has led to the development of small molecules that target genetic mutations known to play 
critical roles in the progression to metastatic disease. The discovery of epidermal growth factor 
receptor (EGFR) mutations in 15%–20% of lung adenocarcinomas and the associated response 
to EGFR tyrosine kinase inhibitors have provided a successful avenue of attack in late-stage 
adenocarcinomas. Use of the EGFR tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib 
is limited to patients who have adenocarcinomas with known activating EGFR mutations. 
  However, the EGFR mutation testing landscape is varied and includes many screening and 
targeted methods, each with its own benefits and limitations. These tests can simplify the drug 
discovery process, make clinical trials more efficient and informative, and individualize cancer 
therapy. In practice, the choice of method should be determined by the nature of the sample to be 
tested, the testing laboratory’s expertise and access to equipment, and whether the detection of 
only known activating EGFR mutations, or of all possible mutations, is required.   Development 
of companion diagnostic tests for this identification is advancing; nevertheless, the use of such 
tests merits greater attention.
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Introduction
Lung cancer is the leading cause of cancer-related death in the United States and 
it accounts for more than 1 million deaths worldwide each year.1 In recent years, 
the diagnosis and treatment of patients with advanced lung cancer have undergone 
transformational changes. The current paradigm for prescribing novel targeted 
therapies is based on selecting patients according to the presence of specific onco-
genic abnormalities in the tumor.2 The first of such abnormalities discovered in lung 
cancer were epidermal growth factor receptor (EGFR) kinase domain mutations; 
tumors with these mutations were found to be sensitive to EGFR tyrosine kinase 
inhibitors (TKIs).3
Aside from the primary non-small-cell lung cancer (NSCLC) driver oncogenes 
(KRAS, EGFR, and ALK, which are mutated in more than 5% of NSCLC), several 
known or potential lung cancer oncogenes are mutated in ,5% of cases. However, 
because lung cancer is a major lethal disease, detection of a mutation that occurs even 
at low rates could represent many affected patients and thus should not be ignored – 
especially mutations that are actionable for developing new targeted therapies.4 We 
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highlighting the available methods to identify those most 
likely to benefit from treatment with EGFR-targeted 
therapy.
Targeted treatment of mutated 
EGFR-expressing NSCLC
First-generation eGFR TKis
Causative EGFR mutations, either a deletion in exon 19 or an 
amino acid substitution at codon 858 in exon 21 (L858R),5,6 
were present in 16.6% of Spanish NSCLC patients, and 
more frequently in adenocarcinomas in females (30%) and 
never-smokers (37.7%).7 Gefitinib and erlotinib are first-
generation reversible EGFR TKIs approved for treatment of 
EGFR-mutant NSCLC. Both selectively bind to the adenos-
ine triphosphate-binding site of the receptor. A third first-
generation inhibitor, icotinib, is currently undergoing clinical 
trials, and previous studies have demonstrated its decreased 
toxicity profile and similar efficacy to gefitinib.8,9
Gefitinib received accelerated approval in 2003 for 
patients with advanced NSCLC based on studies that demon-
strated rare but dramatic responses in unselected patients.10,11 
However, in 2005, given the lack of a significant survival 
benefit compared to best supportive care, US Food and 
Drug Administration (FDA) approval was withdrawn for 
all patients except those who had previously benefited from 
the drug.12
In 2009, NSCLC patients receiving gefitinib as a first-line 
therapy in the IPASS trial13 had a longer progression-free 
survival (PFS) compared to those receiving carboplatin 
plus paclitaxel. When the impact of therapy was based on 
patients’ genotype, the PFS for those with EGFR-mutant 
tumors was significantly longer among patients who received 
gefitinib than those treated with chemotherapy (9.5 versus 
6.3 months, hazard ratio [HR] =0.48; 95% confidence interval 
[CI] =0.36–0.64; P,0.001).13 However, the median overall 
survival (OS) was similar in both study arms.13
One year later, two subsequent Phase III trials conducted 
in Asian populations of EGFR-mutant positive patients con-
firmed the findings from the IPASS study. The   North-East 
Japan Study Group trial14 demonstrated a PFS of 10.4 months 
with first-line gefitinib compared to 5.5 months with che-
motherapy (HR =0.30; 95% CI =0.22–0.41; P,0.001), 
although the WJTOG3405 study15 found a PFS of 9.2 months 
with gefitinib compared to 6.3 months with chemotherapy 
(HR =0.489; 95% CI =0.336–0.710; log-rank, P,0.0001).
The OPTIMAL16 and EURTAC trials3 were published 
in 2011 and 2012, respectively, and they confirmed a PFS 
benefit for EGFR-mutant NSCLC treated with erlotinib 
when compared to standard chemotherapy in first-line 
therapy. TKI-sensitizing mutations (exon 19 deletion or 
exon 21 L858R mutation) were mandatory for enrollment 
in these studies. The OPTIMAL study16 demonstrated a 
PFS of 13.1 months with first-line erlotinib compared to 
4.6 months with gemcitabine plus carboplatin (HR =0.16; 
95% CI =0.66–0.99; P=0.037) in a Chinese population. 
The EURTAC study3 compared standard platinum doublet 
chemotherapy to erlotinib in the first-line setting for EGFR-
mutant NSCLC in a European population. Again, a significant 
improvement in PFS in favor of the erlotinib arm over stan-
dard chemotherapy (PFS 9.7 months versus 5.2 months; HR 
=0.37; 95% CI =0.25–0.54; P.0.0001) was observed. Based 
on these results, in May 2013, erlotinib was approved by the 
US FDA for the first-line treatment of patients with NSCLC 
whose tumors harbor causative EGFR mutations.
Although EGFR TKIs, such as erlotinib or gefitinib, 
are standard treatment for patients with EGFR-mutant 
NSCLC,17 the median PFS still does not exceed 10 months3 
and no combination therapies have yet been incorporated 
into clinical practice to overcome potential mechanisms of 
failure to single EGFR TKIs. Among patients progressing 
on first-generation EGFR TKIs, 50% have tumors with a 
secondary T790M mutation.18 The emergence of the T790M 
EGFR gatekeeper mutation and upregulation of downstream 
signaling by MET amplification have been described as the 
two main mechanisms responsible for acquired resistance.19 
However, a Phase III trial20 enrolling only patients with 
MET-positive tumors was stopped in early March 2014 due 
to futility; there was no evidence to suggest a positive effect 
of the addition of onartuzumab to erlotinib.
In a recent report, the combination of bevacizumab and 
erlotinib in the first-line setting was superior to erlotinib 
alone in patients with EGFR-mutant NSCLC. Remarkably, 
the combination had a median PFS of 16.0 months 
versus 9.7 months for erlotinib alone (HR =0.54; 95% 
CI =0.36–0.79; P=0.0015).21 Other studies, such as 
BELIEF17 (NCT01562028), and an ongoing in US trial 
(NCT01532089), are being carried out with the combination 
of erlotinib and bevacizumab with the primary objective of 
clarifying the role of this combination in the subgroup of 
EGFR-mutant NSCLC patients who also harbor the EGFR 
T790M mutation.22 These studies pave the way to move 
from single EGFR TKIs to combination therapy to improve 
outcomes in EGFR-mutant NSCLC. If the clinical benefit 
of the combination of EGFR TKIs with vascular endothelial 
growth factor (VEGF)-targeted therapies is further vali-
dated, additional research could be warranted to prevent the Lung Cancer: Targets and Therapy 2014:5 submit your manuscript | www.dovepress.com
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  occurrence of possible novel mechanisms of resistance to 
VEGF-targeted therapies.
Second- and third-generation eGFR TKis
Second-generation EGFR TKIs were developed to overcome 
resistance to first-generation inhibitors. Currently, there are 
two lead second-generation EGFR TKI candidates, afatinib 
and dacomitinib, which are active against EGFR mutations 
with acquired resistance to erlotinib or gefitinib.23 These 
drugs have the advantage of forming covalent, irreversible 
bonds with the target, which increases their effectiveness 
through the prolonged inhibition of EGFR signaling. It is 
hypothesized that prolonged and irreversible inhibition of 
the receptor has the potential for further improvement in 
response to treatment over first-generation TKIs.
Afatinib was recently approved for the first-line treat-
ment of EGFR-mutant NSCLC in the US and for treatment 
of EGFR-mutant TKI-naïve patients in Europe and Japan. 
The approval was based on data from the pivotal LUX-Lung 
3 trial,24 which compared afatinib to chemotherapy with 
pemetrexed plus cisplatin. The trial showed that patients on 
afatinib had a PFS of 13.6 months versus 6.9 months for 
chemotherapy (HR =0.47; 95% CI =0.34–0.65; P=0.001).24 
In the LUX-Lung 6 trial,25 afatinib was compared to 
gemcitabine plus cisplatin for patients with EGFR mutations. 
PFS with afatinib was 11.0 months versus 5.6 months with 
chemotherapy (HR =0.28; 95% CI =0.20–0.39; P,0.0001).25 
Notably, a recent pooled analysis of these two trials revealed 
an OS benefit for the afatinib arm (median OS: 27.3 months 
versus 24.3 months; HR =0.81; 95% CI =0.66–0.99; P=0.037) 
with the majority of benefit observed for patients with exon 
19 deletions (median OS: 31.7 months versus 20.7 months; 
HR =0.59; 95% CI =0.45–0.77; P,0.001).26 Of note, some 
patients with uncommon de novo T790M and exon 20 inser-
tions appeared to derive a benefit from afatinib.27
The second-generation EGFR TKI, dacomitinib, is a 
pan-human epidermal growth factor receptor (HER) inhibitor 
that irreversibly binds to EGFR, HER2, and HER4 tyrosine 
kinases.28 Preclinical studies have demonstrated antitumor 
activity in NSCLC cell lines with sensitive and resistant 
EGFR mutations.28 A Phase I dose-escalation study29 of 
dacomitinib in 121 patients with advanced solid tumors (57 of 
whom had NSCLC) established the maximum tolerated dose 
as 45 mg/day, with dose-limiting toxicities of stomatitis and 
skin toxicities. Subsequent randomized studies comparing 
dacomitinib with erlotinib in unselected NSCLC populations 
of previously treated NSCLC patients failed to demonstrate 
significant improvement in outcomes.30,31 However, the role of 
dacomitinib as a first-line therapy in patients with activating 
EGFR mutations has not yet been explored.
We recently reported the possible causes of resistance 
to EGFR TKIs in EGFR-mutant NSCLC patients: the high 
coexistence of the pretreatment somatic T790M mutation 
with a clear impact on PFS; and the role of BIM messenger 
RNA expression as an independent prognostic marker.22 
Pretreatment T790M can be detected in more than 60% of 
patients.22 In fact, using a peptide nucleic acid (PNA) clamp 
polymerase chain reaction (PCR) assay, pretreatment T790M 
mutations were detected in 65.26% of patients.22 These results 
reinforce the need for second- and third-generation EGFR 
TKIs, without forgetting the existing data that suggest the 
use of erlotinib or gefitinib beyond progression, with added 
chemotherapy, radiotherapy, or best supportive care as a way 
to improve survival.32
CO-1686 is a novel covalent inhibitor that irreversibly 
and selectively targets both the initial activating EGFR 
mutations and the T790M secondary acquired resistance 
mutation.33 To investigate its use as a single agent, CO-1686 
is being evaluated in a Phase I/II trial34 in EGFR-mutant 
NSCLC patients previously treated with first-line gefitinib 
or erlotinib (NCT01526928). In the Phase I study, and based 
on early findings from the ongoing Phase II trial, the agent 
yielded a 58% overall response rate across all dose levels 
in trial participants with biopsy-confirmed EGFR T790M 
mutations. Additionally, the compound did not cause the rash 
and diarrhea commonly associated with earlier generations 
of EGFR inhibitors.35
AZD9291 showed high activity in preclinical studies and 
was well tolerated in animal models. Xenograft studies identi-
fied a breakdown metabolite of AZD9291 called AZ5104 that 
is approximately five times as potent as AZD9291 itself.36 
In the Phase I study37 of AZD9291 in EGFR-mutant patients 
resistant to standard EGFR TKIs, 50% of patients experi-
enced tumor shrinkage and the drug worked particularly well 
in patients with the T790M mutation.
Companion diagnostics
There is a growing trend toward the extensive molecular 
characterization of tumors to select the most appropriate 
therapy. The benefits of EGFR TKI treatment can be 
maximized if used with clinically validated and accurate 
companion   diagnostics. Robust and accurate assays with 
rapid turnaround time are preferred. Important factors in 
assay performance include analytic standardization, valida-
tion of reagents and methodology, laboratory experience, 
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  quality assurance studies to ascertain the mutation status of 
a standard panel of tumors have shown that different clinical 
laboratories do not correctly identify the mutation status of 
100% of the panel members, even when using identical or 
similar testing methodologies.38,39
In July 2011, the US FDA released a draft guidance 
to explain its policy requiring the review and regulatory 
approval of companion diagnostics as essential tools to guide 
the use of corresponding therapies.40 The guidance, aimed 
at stimulating early collaborations between drug and device 
makers, clarified the US FDA’s definition of a companion 
diagnostic; it recommended the early interaction between 
drug and device manufacturers and the US FDA, and it identi-
fied instances in which the US FDA may approve a targeted 
treatment in the absence of a cleared or approved companion   
diagnostic. For instance, the US FDA may decide to approve 
a drug even though the indicated in vitro companion diagnos-
tic device is not US FDA-approved, particularly in diseases 
like cancer, for which no satisfactory alternative treatments 
exist. In these patients, the benefits of using the drug with an 
unapproved or uncleared in vitro companion diagnostic are 
so clear as to outweigh the risks associated with the lack of 
an approved in vitro companion diagnostic device.
DNA mutational analysis is the preferred method to assess 
EGFR status. A multitude of techniques have been developed 
as potential alternatives to the historical standard for EGFR 
mutation testing – specifically, direct DNA sequencing. 
Direct sequencing has low sensitivity, can be complex and 
time consuming, and is not standardized in terms of labora-
tory practice.41 However, these novel techniques have varying 
sensitivities to detect known and de novo mutations, with 
differing instruments reagents, assay run times, and costs.42 
The PNA-PCR clamp assay is one method capable of detect-
ing EGFR mutations in a background of wild-type EGFR.3 
This method employs fluorescent primers with preferred 
amplification of the mutant sequence, which is then detected 
by locked nucleic acids to increase specificity. The sensitivity 
and specificity of the PNA-PCR clamp method are 97% and 
100%, respectively.43
Many commercial EGFR mutation detection kits are avail-
able, including those from Genzyme Corporation (Cambridge, 
MA, USA) and Qiagen NV (Venlo, The   Netherlands). The 
Roche cobas® EGFR Mutation Test (a real-time, PCR-based 
diagnostic test) (Hoffman-La Roche Ltd, Basel, Switzerland) 
is CE-marked and identifies 41 mutations across exons 18, 
19, 20, and 21. In parallel with the approval of erlotinib 
as a first-line treatment for patients who harbor the EGFR 
mutation, the US FDA announced the approval of the cobas 
EGFR Mutation Test as a companion diagnostic for erlotinib, 
making it the first US FDA-approved companion diagnostic 
able to detect EGFR mutations. The safety and effectiveness 
of the cobas EGFR Mutation Test was established through 
the retrospective analysis of a clinical validation study in a 
subset of lung cancer specimens from patients screened in 
the EURTAC trial.44 The test demonstrated improved sample 
workflow relative to the laboratory-developed tests used in 
the trial, enabling EGFR mutation screening in a single assay 
with a 1-day turnaround time. The EGFR PCR test was highly 
concordant (.96%) with the laboratory-developed tests to 
select patients for the EURTAC trial,44 and it showed superior 
sensitivity and specificity when compared with conventional 
Sanger sequencing.
In July 2013, the US FDA approval of the Scorpion 
  Amplified Refractory Mutation System therascreen® EGFR 
Rotor-Gene® Q PCR kit (therascreen EGFR assay;   Qiagen 
NV) was followed by the US FDA priority review of   afatinib. 
Recently, a high concordance rate (98.0%) of the cobas 
EGFR assay with the therascreen EGFR assay has been 
demonstrated.45 In the study from Kimura et al,45 both assays 
proved to be simple, validated methods for detecting the most 
common, clinically significant EGFR mutations, and they 
proved to be helpful for appropriate treatment guidance for 
NSCLC patients. However, the cobas EGFR assay has two 
advantages over the therascreen assay: first, it takes only 8 hours 
to go from the tumor specimen to the results, and patients can 
begin the most appropriate treatment within a shorter time; 
second, only a very small amount of DNA is required to detect 
tumor mutation status.45 In Table 1, we have summarized the 
main techniques for EGFR mutation testing.
Testing of tumor tissue remains the recommended method 
for detecting the presence of causative EGFR mutations. 
  However, little tumor tissue may be obtained by biopsy, espe-
cially in advanced NSCLC, raising the question of whether 
circulating tumor (ct)DNA may be used as a surrogate liquid 
biopsy for the noninvasive assessment of EGFR mutations. The 
first blood-based EGFR mutation analysis was performed in 
serum obtained from Japanese patients with NSCLC before gefi-
tinib treatment, using Scorpion Amplified Refractory Mutation 
System technology. EGFR mutation status in tumor tissue was 
consistent with that in serum in 72.7% of the paired samples.46 
This finding indicated the feasibility of using serum DNA for 
the detection of EGFR mutations, and since then, several stud-
ies have assessed EGFR mutations in serum or plasma using 
different methods.47–53 The rate of detection of EGFR mutations 
in ctDNA varies   according to the method used.46,48,49,52,54–62 
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methods reported a pooled sensitivity rate of 64.5%, but it 
was found that the results were influenced by the test method 
(P=0.04).63 Therefore, the sensitivity of EGFR mutation testing 
in ctDNA still requires further improvement.
Conclusion
Personalized therapy for NSCLC patients should include a 
genetic assessment of EGFR mutational status for individual 
patients. Erlotinib, gefitinib, and afatinib are currently avail-
able as treatments for patients with advanced NSCLC who 
harbor EGFR mutations. Until now, no head-to-head trials 
between these TKIs in populations with the EGFR mutation 
have been reported, which provides room for indirect and 
integrated comparisons. In addition, the appropriate role of 
routine EGFR mutation analysis in the treatment of patients 
with NSCLC is constantly evolving. These issues should form 
the basis for new prospective clinical studies investigating 
new standards of care to determine which of the different 
EGFR TKIs is best, and to ensure adequate documentation of 
the patient’s EGFR mutation status in the preclinical setting, 
during the treatment, and during follow-up.
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J 
Clin. 2014;64(1):9–29.
2.  Karachaliou N, Rosell R, Morales-Espinosa D, Viteri S. Systemic treat-
ment in EGFR-ALK NSCLC patients: second line therapy and beyond. 
Expert Rev Anticancer Ther. 2014;14(7):807–815.
3.  Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group 
in collaboration with Groupe Français de Pneumo-Cancérologie and 
Associazione Italiana Oncologia Toracica. Erlotinib versus standard 
chemotherapy as first-line treatment for European patients with advanced 
EGFR mutation-positive non-small-cell lung cancer (EURTAC): 
a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 
2012;13(3):239–246.
4.  Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat 
Med. 2012;18(3):349–351.
5.  Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung 
adenocarcinomas induced in mice by mutant EGF receptors found in 
human lung cancers respond to a tyrosine kinase inhibitor or to down-
regulation of the receptors. Genes Dev. 2006;20(11):1496–1510.
  6.  Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain 
mutations on lung tumorigenesis and in vivo sensitivity to EGFR-
targeted therapies. Cancer Cell. 2006;9(6):485–495.
  7.  Rosell R, Moran T, Queralt C, et al; Spanish Lung Cancer Group. 
Screening for epidermal growth factor receptor mutations in lung cancer. 
N Engl J Med. 2009;361(10):958–967.
  8.  Gu A, Shi C, Xiong L, Chu T, Pei J, Han B. Efficacy and safety evalu-
ation of icotinib in patients with advanced non-small cell lung cancer. 
Chin J Cancer Res. 2013;25(1):90–94.
  9.  Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously 
treated advanced non-small-cell lung cancer (ICOGEN): a ran-
domised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 
2013;14(10):953–961.
  10.  Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor 
of the epidermal growth factor receptor tyrosine kinase, in symptomatic 
patients with non-small cell lung cancer: a randomized trial. JAMA. 
2003;290(16):2149–2158.
  11.  Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized 
phase II trial of gefitinib for previously treated patients with advanced 
non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin 
Oncol. 2003;21(12):2237–2246.
  12.  Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive 
care in previously treated patients with refractory advanced non-
small-cell lung cancer: results from a randomised, placebo-controlled, 
multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 
2005;366(9496):1527–1537.
  13.  Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-
paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10): 
947–957.
  14.  Maemondo M, Inoue A, Kobayashi K, et al; North-East Japan Study 
Group. Gefitinib or chemotherapy for non-small-cell lung cancer with 
mutated EGFR. N Engl J Med. 2010;362(25):2380–2388.
  15.  Mitsudomi T, Morita S, Yatabe Y, et al; West Japan Oncology Group. 
Gefitinib versus cisplatin plus docetaxel in patients with non-small-
cell lung cancer harbouring mutations of the epidermal growth factor 
receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet 
Oncol. 2010;11(2):121–128.
  16.  Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line 
treatment for patients with advanced EGFR mutation-positive non-small-
cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, 
randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742.
  17.  Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in person-
alisation of lung cancer treatment. Lancet. 2013;382(9893):720–731.
  18.  Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in 
non-small cell lung cancer on progression-free and overall survival:   
a meta-analysis. J Natl Cancer Inst. 2013;105(9):595–605.
  19.  Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and 
histological evolution of lung cancers acquiring resistance to EGFR 
inhibitors. Sci Transl Med. 2011;3(75):75ra26.
  20.  Spigel DR, Edelman MJ, O’Byrne K, et al. Onartuzumab plus erlotinib 
versus erlotinib in previously treated stage IIIb or IV NSCLC: results 
from the pivotal phase III randomized, multicenter, placebo-controlled 
METLung (OAM4971g) global trial [abstract]. J Clin Oncol. 2014; 
32 Suppl 5:abstract 8000.
Table 1 Primary techniques for EGFR mutation testing
Direct DNA sequencing
Historical standard for EGFR mutation testing Low sensitivity, complex, time-consuming, not standardized in terms 
of laboratory practice
PCR assays
PNA-PCR clamp assay Simple, validated methods for detecting the most common, clinically 
significant EGFR mutations. Superior sensitivity and specificity 
compared with conventional Sanger sequencing. Not time consuming, 
require small amount of DNA
Cobas® EGFR Test; first FDA-approved companion diagnostic
Therascreen® EGFR assay; FDA-approved companion diagnostic
Abbreviations: PCR, polymerase chain reaction; PNA, peptide nucleic acid; US FDA, United States Food and Drug Administration.Lung Cancer: Targets and Therapy 2014:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
78
Karachaliou and Rosell
  21.  Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab 
as first-line therapy in patients with advanced non-squamous non-
small-cell lung cancer harbouring EGFR mutations (JO25567): an 
open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 
2014;15(11):1236–1244. 
  22.  Costa C, Molina MA, Drozdowskyj A, et al. The impact of EGFR 
T790M mutations and BIM mRNA expression on outcome in 
patients with EGFR-mutant NSCLC treated with erlotinib or chemo-
therapy in the randomized phase III EURTAC trial. Clin Cancer Res. 
2014;20(7):2001–2010.
  23.  Ou S. Second-generation irreversible epidermal growth factor recep-
tor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap?   
A review of the clinical evidence. Crit Rev Oncol Hematol. 2012;83(3): 
407–421.
  24.  Sequist LV , Yang JC, Yamamoto N, et al. Phase III study of afa-
tinib or cisplatin plus pemetrexed in patients with metastatic lung 
adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27): 
3327–3334.
  25.  Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine 
for first-line treatment of Asian patients with advanced non-small-cell 
lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, 
randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–222.
  26.  Chih-Hsin Yang J, Sequist LV , Schuler MH, et al. Overall survival (OS) 
in patients (pts) with advanced non-small cell lung cancer (NSLCL) 
harboring common (Del19/L858R) epidermal growth factor recep-
tor mutations (EGFR mut): pooled analysis of two large open-label 
phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) compar-
ing afatinib with chemotherapy (CT) [abstract]. J Clin Oncol. 2014; 
32 Suppl 5:abstract 8004.
  27.  Yang JC, Sequist LV , Geater S, et al. Activity of afatinib in uncom-
mon epidermal growth factor receptor (EGFR) mutations: findings 
from three trials of afatinib in EGFR mutation-positive lung cancer. 
World Congress on Lung Cancer; October 27–31; 2013; Sydney, 
Australia.
  28.  Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irrevers-
ible pan-ERBB inhibitor, is effective in lung cancer models with EGFR 
and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007; 
67(24):11924–11932.
  29.  Jänne PA, Boss DS, Camidge DR, et al. Phase I dose-escalation study of 
the pan-HER inhibitor, PF299804, in patients with advanced malignant 
solid tumors. Clin Cancer Res. 2011;17(5):1131–1139.
  30.  Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized 
phase II study of dacomitinib (PF-00299804), an irreversible pan-
human epidermal growth factor receptor inhibitor, versus erlotinib in 
patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012; 
30(27):3337–3344.
  31.  Ramalingam SS, Janne PA, Mok T, et al. Randomized, double-blinded 
study of dacomitinib, an irreversible pan-human epidermal growth 
factor receptor (HER) inhibitor, versus erlotinib for second-line/third-
line therapy of locally advanced/metastatic non-small cell lung cancer 
(ARCHER 1009) [abstract]. J Clin Oncol. 2014;32 Suppl 5:abstract 
8018.
  32.  Faehling M, Eckert R, Kamp T, et al. EGFR-tyrosine kinase inhibitor 
treatment beyond progression in long-term Caucasian responders to 
erlotinib in advanced non-small cell lung cancer: a case-control study 
of overall survival. Lung Cancer. 2013;80(3):306–312.
  33.  Mu X, Lin S, Yang J, et al. TGF-β signaling is often attenuated during 
hepatotumorigenesis, but is retained for the malignancy of hepatocel-
lular carcinoma cells. PLoS One. 2013;8(5):e63436.
  34.  Berardi R, Santoni M, Morgese F, et al. Novel small molecule EGFR 
inhibitors as candidate drugs in non-small cell lung cancer. Onco Targets 
Ther. 2013;6:563–576.
  35.  Sequist LV , Soria JC, Shirish M, et al. First-in-human evaluation of 
CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of 
mutations of EGFR (activating and T790M) [abstract]. J Clin Oncol. 
2014;32 Suppl 5:abstract 8010.
  36.  Targeting resistance in lung cancer. Cancer Discov. 2013;3(12):OF9.
  37.  Janne PA, Ramalingam SS, Chih-Hsing Yang J, et al. Clinical activity 
of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) 
with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC) 
[abstract]. J Clin Oncol. 2014;32 Suppl 5:abstract 8009.
  38.  Beau-Faller M, Degeorges A, Rolland E, et al. Cross-validation study 
for epidermal growth factor receptor and KRAS mutation detection in 
74 blinded non-small cell lung carcinoma samples: a total of 5550 exons 
sequenced by 15 molecular French laboratories (evaluation of the EGFR 
mutation status for the administration of EGFR-TKIs in non-small 
cell lung carcinoma [ERMETIC] project – part 1). J Thorac Oncol. 
2011;6(6):1006–1015.
  39.  Bellon E, Ligtenberg MJ, Tejpar S, et al. External quality assessment 
for KRAS testing is needed: setup of a European program and report 
of the first joined regional quality assessment rounds. Oncologist. 
2011;16(4):467–478.
  40.  US Food and Drug Administration. In Vitro Companion Diagnostic 
Devices – Guidance for Industry and Food and Drug   Administration 
Staff. Silver Spring, MD: US Food and Drug Administration;   
2014.
  41.  Penzel R, Sers C, Chen Y, et al. EGFR mutation detection in 
NSCLC – assessment of diagnostic application and recommendations 
of the German Panel for Mutation Testing in NSCLC. Virchows Arch. 
2011;458(1):95–98.
  42.  Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the 
epidermal growth factor receptor in non-small cell lung cancer cell 
lines revealed by a rapid and sensitive detection system, the peptide 
nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005;65(16): 
7276–7282.
  43.  Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung 
cancer patients with epidermal growth factor receptor gene mutations 
screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J 
Cancer. 2006;95(11):1483–1489.
  44.  Benlloch S, Botero ML, Beltran-Alamillo J, et al. Clinical validation 
of a PCR assay for the detection of EGFR mutations in non-small-cell 
lung cancer: retrospective testing of specimens from the EURTAC trial. 
PLoS One. 2014;9(2):e89518.
  45.  Kimura H, Ohira T, Uchida O, et al. Analytical performance of the 
cobas EGFR mutation assay for Japanese non-small-cell lung cancer. 
Lung Cancer. 2014;83(3):329–333.
  46.  Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal 
growth factor receptor mutations in serum as a predictor of the response 
to gefitinib in patients with non-small-cell lung cancer. Clin Cancer 
Res. 2006;12(13):3915–3921.
  47.  Horiike A, Kimura H, Nishio K, et al. Detection of epidermal growth 
factor receptor mutation in transbronchial needle aspirates of non-small 
cell lung cancer. Chest. 2007;131(6):1628–1634.
  48.  He C, Liu M, Zhou C, et al. Detection of epidermal growth factor recep-
tor mutations in plasma by mutant-enriched PCR assay for prediction 
of the response to gefitinib in patients with non-small-cell lung cancer. 
Int J Cancer. 2009;125(10):2393–2399.
  49.  Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 
is commonly inactivated by somatic mutations and 3p21.1 losses in 
malignant pleural mesothelioma. Nat Genet. 2011;43(7):668–672.
  50.  Taniguchi K, Uchida J, Nishino K, et al. Quantitative detection 
of EGFR mutations in circulating tumor DNA derived from lung 
adenocarcinomas. Clin Cancer Res. 2011;17(24):7808–7815.
  51.  Maheswaran S, Sequist LV , Nagrath S, et al. Detection of mutations 
in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359(4): 
366–377.
  52.  Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM. Single-molecule 
detection of epidermal growth factor receptor mutations in plasma by 
microfluidics digital PCR in non-small cell lung cancer patients. Clin 
Cancer Res. 2009;15(6):2076–2084.
  53.  Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of 
response and resistance in EGFR-mutant lung cancer using quantitative 
next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 
2014;20(6):1698–1705.Lung Cancer: Targets and Therapy
Publish your work in this journal
Lung Cancer: Targets and Therapy is an international, peer-reviewed, open access 
journal focusing on lung cancer research, identification of therapeutic targets and 
the optimal use of preventative and integrated treatment interventions to achieve 
improved outcomes, enhanced survival and quality of life for the cancer patient. 
Specific topics covered in the journal include: Epidemiology, detection and screening; 
Cellular research and biomarkers; Identification of biotargets and agents with novel 
mechanisms of action; Optimal clinical use of existing anticancer agents, including 
combination therapies; Radiation and surgery; Palliative care; Patient adherence, 
quality of life, satisfaction; Health economic evaluations. The manuscript manage-
ment system is completely online and includes a very quick and fair peer-review 
system. Visit http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Submit your manuscript here: http://www.dovepress.com/lung-cancer-targets--therapy-journal
Lung Cancer: Targets and Therapy 2014:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
79
Treatment of non-small-cell lung cancer
  54.  Hu C, Liu X, Chen Y, et al. Direct serum and tissue assay for EGFR 
mutation in non-small cell lung cancer by high-resolution melting 
analysis. Oncol Rep. 2012;28(5):1815–1821.
  55.  Kim ST, Jung HY, Sung JS, et al. Can serum be used for analyzing the 
EGFR mutation status in patients with advanced non-small cell lung 
cancer? Am J Clin Oncol. 2013;36(1):57–63.
  56.  Jiang B, Liu F, Yang L, et al. Serum detection of epidermal growth 
factor receptor gene mutations using mutant-enriched sequencing in 
Chinese patients with advanced non-small cell lung cancer. J Int Med 
Res. 2011;39(4):1392–1401.
  57.  Bai H, Wang Z, Chen K, et al. Influence of chemotherapy on EGFR 
mutation status among patients with non-small-cell lung cancer. J Clin 
Oncol. 2012;30(25):3077–3083.
  58.  Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor 
mutations in plasma DNA samples predict tumor response in Chinese 
patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol. 
2009;27(16):2653–2659.
  59.  Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor recep-
tor mutation status in circulating free DNA in serum: from IPASS,   
a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell 
lung cancer. J Thorac Oncol. 2012;7(1):115–121.
  60.  Yam I, Lam DC, Chan K, et al. EGFR array: uses in the detection of 
plasma EGFR mutations in non-small cell lung cancer patients. J Thorac 
Oncol. 2012;7(7):1131–1140.
  61.  Zhao X, Han RB, Zhao J, et al. Comparison of epidermal growth factor 
receptor mutation statuses in tissue and plasma in stage I–IV non-small 
cell lung cancer patients. Respiration. 2013;85(2):119–125.
  62.  Weber B, Meldgaard P, Hager H, et al. Detection of EGFR mutations 
in plasma and biopsies from non-small cell lung cancer patients by 
allele-specific PCR assays. BMC Cancer. 2014;14:294.
  63.  Li Z, Zhang Y, Bao W, Jiang C. Insufficiency of peripheral blood as a 
substitute tissue for detecting EGFR mutations in lung cancer: a meta-
analysis. Target Oncol. Epub March 14, 2014.